When Gilead Sciences' ($GLD) Truvada was approved as an HIV preventative last year, it was hailed as a historic event. It was the first time an HIV drug had been approved to stave off HIV infection, rather than treat those who had already contracted the virus.
President Barack Obama plans to roll out a highly anticipated brain mapping project today, providing details about the ambitious initiative to uncover mysteries about complex brain functions that could lead to new therapies for Alzheimer's and Parkinson's diseases.
Researchers have been testing a compact, self-contained sensor that has been used to record and transmit brain activity data for more than a year in animal studies.
With big budget cutbacks under way at both the NIH and the FDA, drug developers as well as researchers and patient groups are scrambling to lobby the government to protect grants as well as keep all of the industry's user fees committed to drug reviews.
Deep, across-the-board federal spending cuts--totaling $85 billion--are set to go into effect today after Congress and President Barack Obama failed to come to an agreement on a deficit reduction plan. The sequester cuts will no doubt have an impact on scientific and medical research, adding to several years' worth of small cuts and freezes to federal grant funding at government agencies like the National Institutes of Health.
Grappling with major government budget cuts, the FDA is seeking remedies to preserve programs of vital interest to pharma and device companies. Now that sequestration has arrived today, power brokers in the White House and Congress could hold the keys to keeping the agency on track.
A new study showed a glimmer of hope for a troubled nicotine vaccine after a series of clinical trial setbacks, as investigators hold out hope for new weapons against smoking, a leading cause of deadly cancers, lethal lung disease and other fatal ailments. Yet evidence from the latest study could be too scant to win over some skeptics.
CMO Lonza has signed a three-year, $6.9 million agreement with NIH's Center for Regenerative Medicine, signing on to supply stem cells for research purposes.
National Institutes of Health-funded researchers aim to put a stop to Shigella, an illness found most commonly in children, with two related vaccine candidates.
NIH is looping Emory's Rollins School of Public Health into its Parkinson's Disease Biomarker Program, pledging $900,000 to a research team aiming to discover new ways of identifying the ailment.